影像学在胃癌人类表皮生长因子受体2中的研究进展

Advances in Imaging Studies of Human Epidermal Growth Factor Receptor 2 in Gastric Cancer

摘要: 鉴于靶向治疗标志物人类表皮生长因子受体-2 (HER-2)的分子靶向药物已被证实可以显著增加晚期胃癌患者的生存获益，因此，准确评估HER-2状态具有极其重要的意义。然而，病理组织标本的获取通常需要进行有创手段，这不仅增加了患者的痛苦和风险，而且还存在组织获取不足等实际问题。因此，无创评估胃癌HER-2状态的方法成为了当前研究的热点。近年来，随着医学影像技术的不断发展，CT、MRI、PET/CT等影像学方法在评估胃癌HER-2状态方面展现出了巨大的潜力。这些影像学技术不仅可以提供肿瘤的形态学信息，还可以提供肿瘤的生物学特征和分子信息，为预测胃癌HER-2状态提供了新的途径。然而，尽管这些影像学技术在无创评估胃癌HER-2状态方面取得了一定的进展，但仍存在一些挑战和问题。例如，不同成像模式的准确性和可靠性仍需进一步验证，影像组学的分析方法和特征提取仍需优化和完善等。本文主要对近年来正确评估和预测HER-2状态的相关影像学研究及其进展进行综述。

Abstract: Given that molecular targeted drugs targeting the human epidermal growth factor receptor-2 (HER-2) marker have been proven to significantly increase survival benefits in patients with ad-vanced gastric cancer, accurate assessment of HER-2 status is extremely important. However, ob-taining pathological tissue specimens often requires invasive methods, which not only increases pa-tient pain and risk, but also has practical problems such as insufficient tissue acquisition. Therefore, non-invasive methods for assessing the HER-2 status of gastric cancer have become a hot topic in current research. In recent years, with the continuous development of medical imaging techniques, imaging methods such as CT, MRI, and PET/CT have shown great potential in assessing the HER-2 status of gastric cancer. These imaging techniques not only provide morphological information of the tumor but also provide biological and molecular information of the tumor, providing new ave-nues for predicting the HER-2 status of gastric cancer. However, despite the progress made by these imaging techniques in non-invasively assessing the HER-2 status of gastric cancer, there are still some challenges and problems. For example, the accuracy and reliability of different imaging modes still need further validation, and the analysis methods and feature extraction of imaging genomics still need optimization and improvement. This article mainly summarizes the related imaging studies and progress in correctly assessing and predicting HER-2 status in recent years.